Side-by-side comparison of AI visibility scores, market position, and capabilities
Atlanta B2B payments (NYSE: CPAY, rebranded from FLEETCOR) at $3.975B FY2024 revenue; fleet cards, AP automation, Cambridge cross-border payments, Q4 organic growth +12%, adjusted net income $1.4B competing with WEX.
Corpay, Inc. is an Atlanta, Georgia-based B2B payments technology company — publicly traded on the New York Stock Exchange (NYSE: CPAY) as an S&P 500 Financials component (rebranded from FLEETCOR Technologies to Corpay in 2024) — providing corporate fleet card payments, virtual card accounts payable automation, cross-border currency payments, and lodging payment management to corporate, government, and commercial vehicle fleet customers in 100+ countries through approximately 10,000 employees. In fiscal year 2024, Corpay reported record Q4 revenues of $1.034 billion (+10% year-over-year) with organic revenue growth of 12% and adjusted EPS growth of 21%, and full-year revenues of $3.975 billion with adjusted net income of $1.4 billion. The company is organized across three segments: Vehicle Payments (fleet fuel cards, tolling solutions, and vehicle-related expense management — the original FLEETCOR fleet card business), Corporate Payments (virtual cards, AP automation, and cross-border B2B payments through the Cambridge Global Payments platform), and Lodging Payments (corporate lodging payment solutions for trucking, construction, and hospitality workforce programs). CEO Ron Clarke has led Corpay's growth through a decade of acquisitions, rebranding the company as Corpay in 2024 to reflect the expanding portfolio beyond fleet cards into the broader B2B payments market.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.